You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,316,094

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,316,094

Title:	Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
Abstract:	Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
Inventor(s):	Maute; Roy Louis (San Francisco, CA), Weiskopf; Kipp Andrew (Sudbury, MA), Ring; Aaron Michael (New Haven, CT), Weissman; Irving L. (Stanford, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Application Number:	15/518,976
Patent Claims:	1. A composition for increasing phagocytosis of a target cell, the composition comprising: (a) an antibody that specifically binds to leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and does not activate signaling through LILRB1 upon binding; and (b) an agent an antibody that binds to the target cell and thereby opsonizes the target cell. 2. The composition of claim 1, wherein the composition further comprises an anti-CD47/signal regulatory protein alpha (SIRPA) agent. 3. The composition according to claim 1, wherein the antibody that binds to the target cell binds to CD20. 4. The composition according to claim 3, wherein the antibody is rituximab. 5. The composition according to claim 1, wherein the antibody that binds to the target cell binds to EGFR. 6. The composition according to claim 5, wherein the antibody is cetuximab. 7. A method of inducing phagocytosis of a target cell, the method comprising: contacting a target cell with a macrophage in the presence of an antibody that specifically binds to leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) and does not activate signaling through LILRB1 upon binding and an antibody that binds to the target cell and thereby opsonizes the target cell, for a period of time sufficient to induce phagocytosis of the target cell by the macrophage. 8. The method according to claim 7, wherein the target cell is a cancer cell. 9. The method according to claim 7, wherein the target cell is a cell infected with an intracellular pathogen. 10. The method according to claim 7, wherein the target cell is a cancer cell of an individual having cancer, or an infected cell of an individual having a chronic intracellular pathogen infection. 11. The method according to claim 7, wherein the contacting is in vitro or ex vivo. 12. The method according to claim 7, wherein the contacting is in vivo. 13. The method according to claim 7, wherein said contacting is in the presence of an antibody that specifically binds to CD47 and blocks interaction of CD47 and SIRP.alpha.. 14. The method according to claim 7, wherein the antibody that binds to the target cell binds to CD20. 15. The method according to claim 14, wherein the antibody is rituximab. 16. The method according to claim 7, wherein the antibody that binds to the target cell binds to EGFR. 17. The method according to claim 16, wherein the antibody is cetuximab.

Details for Patent 10,316,094

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2034-10-24
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2034-10-24
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2034-10-24
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2034-10-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.